A network meta-analysis shows both PCSK9i and ezetimibe may reduce non-fatal MI and stroke in adults on maximum statin therapy or with statin intolerance who are at very high or high CVD risk but not in those at moderate or low risk.

The National Lipid Association (NLA) has published a new scientific statement on statin intolerance, which includes a new definition and key consideration for ASCVD risk reduction in patients who are statin intolerant.

In a subanalysis of the ODYSSEY OUTCOMES trial, 95% of patients with recent acute coronary syndrome (ACS) achieved LDL-c <1.4 mmol/L when alirocumab was added to optimal statin therapy, instead of only 17% with placebo.

Watch a discussion by three experts on potential mechanisms, side effects, patient selection, parameters for monitoring and future studies with regard to icosapent ethyl.

What are key findings of two CV outcomes trials with icosapent ethyl? Prof. Jukema provides an overview and discusses remaining questions with regard to findings of REDUCE-IT. With poll.

Prof. Zambon talks about established and emerging risk factors that may contribute to residual CV risk in patients who are already being treated with statins.

ACC 2022 A phase 1 study showed that a siRNA targeting LPA mRNA reduced Lp(a) up to 98%. “It is an early study, this has got a long way to go, but we are optimistic that we are beginning an era where we are going to be able to treat this disorder”, Nissen said.

A meta-analysis including data of >4 million patients showed that the prevalence of statin intolerance (SI) is as low as 9.1% and independent of the international definitions.

A study compared the concordance between participant and clinician assessment of eligibility for rosuvastatin 5 mg using an at-home web-based application.

A cost-effectiveness study suggests that population genomic screening for FH in young adults could be cost-effective from a healthcare perspective and cost-saving from a societal perspective at testing costs that are feasible.

ESC 2021 The SANTORINI study aims to investigate whether the 2019 ESC/EAS guidelines for the management of dyslipidemia are being implemented across Europe.

The NHS has made an agreement on a population health management approach in those eligible for the PCSK9 siRNA inclisiran.